Latest News

Kalbe Commences Marketing The Newest COVID-19 drug - Movfor (Molnupiravir), In Collaboration With Amarox (Hetero))

Kalbe Commences Marketing The Newest COVID-19 drug - Movfor (Molnupiravir), In Collaboration With Amarox (Hetero))

Press Release No. 008/KFCP-DIR/PR/II/22

Jakarta, 18 February 2022 – PT Kalbe Farma Tbk (Kalbe) and PT Amarox Global Pharma (Amarox), a subsidiary of globally renowned Indian pharmaceutical company, enters a collaboration to market Movfor (Molnupiravir), the newest antiviral drug used in treatment of COVID-19. The drug itself is recommended for the treatment of COVID-19 on patients over the ager of 18 years old experiencing mild to moderate symptoms, does not require additional oxygen source, and does not have the potential to experience severe COVID-19 related symptoms as stated in the most recent edition of Indonesia COVID-19 Management Guidelines.

Molnupiravir is a novel antiviral that has been granted Emergency Use Authorization (EUA) status by the United States Food and Drug Administration (USFDA) as well as Indonesia National Agency of Drug and Food Control (BPOM RI) for treatment of COVID-19. Movfor the first branded variant of Molnupiravir that has been granted Emergency Use Authorization status by BPOM RI after its official launch earlier this month, 15 February 2022, by Amarox.

Sandeep Sur, General Manager of PT Amarox Pharma Global, mentioned that Movfor has been marketed and used for Covid-19 treatment in India as well as some ASEAN countries.

“Refer to result of Clinical Trial phase 3, Molnupiravir is effective on current SARS-CoV-2 variant and has potential to restrain variant Omicron SARS-CoV-2 infection, resulting on 100% viral clearance by RT PCR result on the 5th day”, explained Sandeep Sur.

“(With this collaboration,) Kalbe will uphold its commitment to support the (Indonesian) government is managing the COVID-19 pandemic as it aligns with Kalbe’s mission to improve health for a better life,” explained Mulia Lie, Director of PT Kalbe Farma, Tbk.

Mulia Lie also expresses his optimism that this collaboration will, hopefully, improve access and accelerate drug availability for treatment of COVID-19 throughout Indonesia, especially with the support of Kalbe’s extensive marketing and distribution infrastructure – 76 distribution outlets spread across 34 provinces and strong partnership with health care professionals, hospitals, and apothecaries.

“Kalbe have collaborated with Amarox as the main marketing and distribution partner for other COVID-19 antiviral drugs that includes: Covifor (Remdesivir) and Fluvir (Oseltamivir), prior to this (press release). The collaboration effort to market of Movfor (Molnufiravir) is a continuation of that engagement. Hopefully, these three antiviral drugs will help with the national availability for COVID-19 treatment drugs that is accessible to the greater public,” added Mulia Lie.

“Understanding the extensive impact COVID-19 pandemic has brought about as well as the recent rapid increase of COVID-19 cases, especially in the past few weeks, PT Amarox Pharma Global (Amarox) continues and expands its collaboration with PT Kalbe Farma, Tbk. to market and distribute Movfor (Molnupiravir) to help improve availability and access to COVID-19 medication for patients throughout Indonesia,” Sandeep Sur continues. 

Kalbe at a glance

PT Kalbe Farma Tbk ("Kalbe") was established in 1966 and is one of the largest listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio: prescription medicines; health product division that handles over-the-counter medication, multivitamins, as well as supplement and ready-to-consume drinks; nutrition division; and distribution & logistics division.

Kalbe has also developed EMOS, a digital service ecosystem for the community that is B2B; and KlikDokter that is a B2C service.  EMOS is an order management application system that makes it easy for distribution channels to manage stock or supply chains; while KlikDokter is a digital platform for health services, especially telemedicine that provides health consultations and health products needed by the community.

Kalbe currently has approximately 40 subsidiaries and 15 production facilities with international standard and employs approximately 16,000 employees dispersed across more than 76 branches throughout Indonesia. Since 1991, Kalbe is listed on the Indonesia Stock Exchange (IDX: KLBF).

2116 Rate this article:

Please login or register to post comments.